Comparing Menopause Care: Symptoms, Treatment Types, and What to Ask

Start with the problem you want care to address

Write down which symptoms interfere most with your day and when they occur. Also record your menstrual history, current medicines, and the questions you want answered. The point is not to arrive with a self-prescribed product; it is to give the clinician a concrete problem to assess.

A service may describe itself broadly as “menopause care.” Ask what it offers for your concern, who assesses it, and when a referral or in-person evaluation might be needed. A long list of products does not answer those questions.

Systemic and local treatment are different decisions

ACOG distinguishes systemic estrogen, which reaches the body through the bloodstream, from low-dose local vaginal treatment. The symptoms being treated affect the choice. For systemic estrogen, whether you have a uterus is an important part of deciding whether a progestogen is needed. Do not assume that a vaginal product and a systemic patch are equivalent because both contain estrogen.

Sources: ACOG: Hormone therapy for menopause

Identify the prescription behind the marketing label

FDA notes that “bioidentical” is not evidence that a compounded hormone is safer or more effective. Approved hormone products also exist with hormones identical to those made by the body. Check the specific product instead of treating the adjective as a quality standard.

Sources: FDA: Menopause and hormone treatment

Use current labeling without turning it into a universal promise

FDA announced boxed-warning changes for an initial six hormone products in February 2026. That is a reason to consult current product information rather than repeat an old warning summary unchanged. It is not a reason to declare every hormone therapy suitable for everyone.

Ask the clinician which label applies to your proposed treatment and how your health history changes the discussion. A broad statement about “HRT” can hide differences between products, routes, and treatment aims.

Sources: FDA: February 2026 hormone-therapy labeling changes

Compare the care arrangement separately from the medicine

Two services could prescribe similar regimens while offering different access to follow-up. Conversely, two similarly priced memberships could propose different medications. Keep those two comparisons separate so an attractive membership price does not decide the clinical question.

• Who conducts the initial consultation and later reviews?
• How are new symptoms, bleeding concerns, or side effects assessed?
• What requires an in-person visit or a referral?
• Can I contact the clinician between scheduled appointments?
• How do prescriptions and records transfer if I leave the service?

Build the complete cost picture

HHS recommends checking the cost of a telehealth visit with the provider or insurer beforehand. For an ongoing menopause program, ask about care fees and pharmacy charges separately. Coverage for one item should not be assumed to cover the whole program.

An invented $60 monthly membership plus $45 in medication charges totals $105 before any other costs. A $90 plan that already includes the same categories of expense could have a lower total. These figures illustrate itemization; they are not provider prices and do not establish comparable treatment.

• Record consultation fees and recurring membership charges.
• List the expected pharmacy charge for every prescribed product.
• Ask about labs or additional visits if required.
• Write down the renewal price, billing interval, and cancellation terms.

Sources: HHS: How do I pay for telehealth?

A short checklist to take to your appointment

The most useful outcome of a comparison is a clear, explainable plan. A score, testimonial, or first-month offer cannot supply that on its own.

• My main symptoms and how they affect daily life.
• My period history, medicines, allergies, and relevant personal or family medical history.
• The proposed treatment’s exact name, route, schedule, and approval status.
• The anticipated benefits, relevant risks, and signs that require medical attention.
• When we will reassess the plan, who to contact, and what the full cost will be.